Skip to content

Association of trimethylamine N-oxide with coronary atherosclerotic burden in patients with non-ST-segment elevation myocardial infarction

Association of trimethylamine N-oxide with coronary atherosclerotic burden in patients with non-ST-segment elevation myocardial infarction

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900022366
Enrollment
Unknown
Registered
2019-04-08
Start date
2019-04-15
Completion date
Unknown
Last updated
2019-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-ST segment Elevation Myocardial Infarction

Interventions

Case series:Nil

Sponsors

Fuwai Hospital Chinese Academy of Medical Sciences, Shenzhen
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: The present study will include two groups of individuals. The first group will include one hundred NSTEMI patients older than 18 years, those who will undergo emergency or primary coronary angiography or percutaneous coronary intervention (PCI) from 15th April 2019 to 15th April 2020. NSTEMI will define according to current ESC guideline as the presence of acute chest pain, but no persistent ST-segment elevation; electrocardiogram (ECG) change may include ST-segment depression =0.05 mV, T-wave inversion =0.3 mV or flat T wave, or transient ST-segment elevation =0.05 mV or may be normal ECG; and positive elevated troponin T or I and/or CK-MB exceeding the upper limit of normal range. The second group will include healthy individuals without known cardiovascular diseases those who will visit for health screen. The second group purpose will provide the reference interval values for TMAO levels compared to the first group.

Exclusion criteria

Exclusion criteria: The exclusion criteria comprises; ST elevation myocardial infarction or stable or unstable coronary artery disease, heart failure, renal or hepatic disease, severe valvular disease, previous history of PCI or CABG, history stroke or bleeding within 3 months, peripheral arterial disease, pregnancy, chronic obstructive lung disease, acute and chronic infection, and history of cancer.

Design outcomes

Primary

MeasureTime frame
TMAO related to NSTEMI;

Countries

China

Contacts

Public ContactKHALID BIN WALEED

Fuwai Hospital Chinese Academy of Medical Sciences, Shenzhen

khalid_khan141@hotmail.com+86 1382439004

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 18, 2026